Cardiac troponin I (cTnl) has been reported to be a highly specific marker for cardiac injury. We investigated the performance of this assay in patients admitted to a coronary care unit for suspected acute myocardial infarction (AMI), patients with extensive skeletal muscle damage, marathon runners and as a routine diagnostic test over a four week period. cTnl proved to be as sensitive a marker for AMI as creatine kinasejMB isoenzyme (CKMB) in patients admitted to the coronary care unit. In 10 patients with a proven AMI, the cTnl remained elevated from 69 to 183 h with a median time of 127 h. Cardiac troponin I had superior specificity to CKMB in patients with skeletal muscle damage. It was very useful in these patients to confirm or exclude concurrent myocardial damage. in routine diagnostic use, cTnI had greater efficiency than CKMB to classify patients as having an AMI. Consequently cTnl should replace CKMB as a marker for AMI.
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In our institution, total creatine kinase (CK) is used as a screening test for the biochemical diagnosis of acute myocardial infarction (AMI). If it is raised or shows a significant increase in a second sample taken 12 h after admission, creatine kinasejMB isoenzyme (CKMB) is used to confirm myocardial damage. CK and CKMB are not specific to cardiac muscle and remain elevated for only 2 to 3 days after an infarct.
CKMB is found in both cardiac and skeletal muscle, albeit at a much lower concentration in the latter.' Hence, for the biochemical diagnosis of AMI, CKMB not only has to exceed an absolute concentration of9 /lgjL, but the CKMB relative index (CKMB in /lgjL expressed as a percentage of total CK in UjL) must be greater than 2,5. 2 Problems may arise when there is concomitant skeletal and cardiac muscle damage. In this situation, while the damaged myocardium may release CKMB and therefore cause it to be elevated, the CKMB relative index may remain within the reference interval because of the much greater amount of CK released from skeletal muscle.' In marathon runners there may Correspondence: Dr C. Bhagat. be increased concentration of CKMB relative to total CK in skeletal muscle." If such individuals present with non-cardiac chest pain, elevated CK and CKMB may falsely suggest myocardial damage.
Some patients may present 2 to 3 days after AMI. In such patients CK activity and CKMB concentration may have returned to within reference intervals.
A biochemical marker which is specific to cardiac muscle and which remains elevated for a much longer period than CKMB would potentially be more useful as a test for myocardial damage. Such a marker appears to be cardiac troponin I (cTnl). There are three isoforms of troponin I, encoded by three different genestwo for skeletal muscle and one for cardiac muscle. cTnl shows about 40% dissimilarity from skeletal muscle troponin I and has an additional 31 amino acids at its N-terminal end."
We have evaluated the clinical usefulness of a new commercial immunoassay for cTnI. We describe the performance of this assay in patients admitted to the coronary care unit (CCU) for suspected AMI, patients with extensive skeletal muscle damage, marathon runners following a 21 km run and as a routine diagnostic test over a 4 week period.
METHODS
Eighty-two patients presenting to the CCU with chest pain were evaluated for AMI. Blood samples were collected on admission and every 12h for 2 days and were assayed for total CK, CKMB and cTnI. Diagnosis of AMI was made by one of the authors (PL), using clinical criteria, i.e. a history of prolonged chest pain, evolving electrocardiographic changes and the rise and fall of total CK. Cardiac troponin I results were not available at the time of diagnosis.
To determine the length of time cTnI remained elevated, cTnI was measured in another 10 patients with an AMI, whenever suitable samples from the patients were received for other biochemical tests. Six of these 10 patients received streptokinase. Six patients with extensive skeletal muscle damage had CK, CKMB, and cTnI measured and eleven athletes (nine of them on two separate occasions) had CK, CKMB and cTnI measured immediately and 24 h after a 21 km road race.
For a 4-week period both CKMB and cTnI were measured whenever CKMB was requested. These samples came from CCU and the general medical wards of the hospital. This permitted the comparison of cTnI with CKMB as a routine diagnostic test. Where there was a discrepancy between CKMB and cTnI as markers for myocardial damage, one of us (PL) reviewed the patient's case notes and made the diagnosis using the criteria described previously.
cTnI was analysed on the Baxter Stratus II (Baxter, Brisbane, Australia) immunoassay analyser. The cTnI assay uses two specific monoclonal antibodies directed at different epitopes, neither of which is directed at the unique N-terminal 31 amino acids present in cTnJ.5 In this assay, cTnI from the sample reacts with immobilized antibody to cardiac troponin I on a glass fibre paper. After incubation a conjugate is added containing enzyme labelled anti-cTnI. The labelled antibody reacts with the immobilized cTnI forming an antibody/antigen/labelledantibody sandwich. The enzyme acts on the substrate, 4-methylumbelliferyl phosphate to release a fluorescent product and the rate of increase in fluorescence is proportional to the concentration of the cTnI in the specimen. This assay has high specificity for cardiac troponin I, Ann Clin Biochem 1997: 34 with cross reactivity of less than 0·1 % with human skeletal muscle troponin J. 5 CKMB concentration was also determined on the Baxter Stratus II immunoassay analyser using two specific antibodies for CKMB in a method similar to that described for cTnI. Total CK was analysed on a Hitachi 747 analyser (Boehringer Mannheim, Sydney, Australia), using an enzymatic method. The reference interval for total CK was 30-180 U/L.
The criteria for myocardial damage were: CKMB concentration greater than 9 !J.g/L and CKMB relative index (CKMB in !J.g/L expressed as a percentage of total CK in U /L) greater than 2·5%. AcTnI concentration greaterthan 1·5!J.g/L was indicative of myocardial damage (manufacturer's recommendation).
The functional sensitivity (defined as the concentration of analyte at which the assay coefficient of variation = 20%) for the cTnI assay was determined to be 0·8 !J.g/L. The coefficients of variation at cTnI values of 2·2, 4'7, 18·7 and 33·6 !J.g/L were 9,8%, 5,9%, 5·0% and 4-4%, respectively. The coefficients of variation for total CK at values of 180 and 500 U/L were 1·6% and 1·0%, respectively. The functional sensitivity for the CKMB assay was I !J.g/L and the coefficients of variation at CKMB values of 13 and 55 !J.g/L were 4·0% and 3·0%, respectively.
RESULTS

Coronary care patients
Twenty-six of 82 patients admitted with chest pain to CCU were subsequently diagnosed as having AMI by conventional criteria. In 24 patients both cTnI and CKMB met the biochemical criteria for myocardial damage. In two patients CKMB was positive before cTnI and in 22 patients CKMB and cTnI were positive at the same time. In one patient cTnI was negative but CKMB was positive and in another cTnI was positive and the CKMB negative. The peak cTnI in 25 patients where it was elevated ranged from 3-4 to 250 !J.g/L, with a median of 20·8 !J.g/L. Figure 1 shows the histogram of peak cTnI in these 25 patients. In four of 25, cTnI was between 3·4 and 10!J.g/L.
Peak cTnI correlated with simultaneously measured CKMB (r=0'74, P<O·OOl). The concentration of CKMB was greater than cTnI with an average ratio of 4·7: I.
An AMI was ruled out in 56 patients. In 47 patients without an AMI the cTnI was less than 0,5, in two between 0·5 and 1'0, in six between 1·0 and I· 5 /lg/L and one patient had a cTnI concentration above the manufacturer's suggested cut-off at 1·7 /lg/L. In five patients in whom an AMI was ruled out, total CK was elevated (range 208-749 U/L). In none of these patients was the CKMB or CKMB relative index positive for an AMI. In 10 patients with AMI where cTnI was determined frequently, cTnI remained elevated from 69 to 183 h with a median of 127 h. Table 1 shows the peak cTnI and the time to peak cTnI and also the time and concentration of the last available raised c'Tnl, Time between onset of symptoms and peak cTnI was not dependent on whether patients were given thrombolytic agent or not. Five of six patients receiving thrombolytic agent had early coronary angiography as part of routine clinical management. Those patients with patent infarct-related artery (patients 5 and 6) had shorter time to peak cTnI than those who had persistent occlusion (patients 2, 3 and 4). The duration of elevation of cTnI is correlated with the time between onset of chest pain and peak cTnI (r=0'83, P<O·OI). Figure 2 shows the changes of cTnI with time after the onset of AMI in four patients, three of whom were given streptokinase.
Patients with skeletal muscle damage Table 2 shows the results of cTnI in six patients who had extensive skeletal muscle damage. In five of these patients cTnI was less than 0·9 /lg/L. In the sixth patient it was 3·7/lg/L. The patient had taken an overdose of paracetamol, trifluoperazine and orphenadrine. She was found unconscious, fitting and had evidence of cardiac toxicity, including sustained ventricular tachycardia requiring cardioversion with lignocaine.
Athletes
The athletes ran a total of 20 races. The median (range) for CK, CKMB and cTnI immediately after the race were 301 (199-953) U/L, 3·1 (1'7-19'7) /lg/L and <0·5 «0·5--0·9) /lg/L respectively; 24 h after the race they were 652 (274-3440) U/L, 4·6 (0'6-22,4) /lg/L and <0·5 «0·5 to 0,9) /lg/L. While CKMB exceeded 9/lg/L in two of 20 samples immediately after the race and in five of 20 at 24 h after the race, in none of the samples did the CKMB relative index reach 2·5%.
Routine diagnostic trial
During the 4 weeks when CKMB was measured as well as cTnI, there were 99 samples from 72 patients when either CKMB or cTnI met the biochemical criteria for myocardial damage. There were 62 samples when both CKMB and cTnI were positive. These were not investigated TABLE Early samples from four patients were positive for CKMB and negative for cTnI, but subsequent samples were positive for cTnI.
Total creatine kinase (CK) activity, creatine kinase MB isoenzyme (CKMB) concentration, CKMB relative index (Rl-s-see text) and cardiac troponin I (cTnI) concentration in patients with acute myocardial infarction
In 22 samples, CKMB was negative and cTnI was positive. Eight of these samples were taken late after the onset of chest pain, previous samples from these patients having been positive for CKMB. This left 14 samples from nine patients where CKMB was negative and cTnI was positive. The results from the nine patients are shown in Table 3 . In patients 17 to 20 CKMB exceeded 9 Ilg/L but the CKMB relative index was less than 2·5%. In patients 17,18 and 19 there was both skeletal muscle as well as myocardial damage. Patient 17 had coronary artery bypass graft, patient 18 had multiple defibrillations and patient 19 had a fall at the time of onset of AMI. In patient 20 CKMB relative index just failed to make the criteria for In subjects 22 and 23, while CKMB did not exceed 9 Ilg/L, the relative index was greater than 2·5%. Patients 24 and 25 had septicaemia but no clinical evidence of myocardial damage. In 11 samples from seven patients CKMB was positive for myocardial damage but cTnI was not. The results from these seven patients are shown in Table 4 . In patient 26 only one sample was taken before the patient died. In patients 27 to 31 there was no clinical evidence of myocardial damage. Patient 32 presented with severe dyspnoea in the absence of chest pain and with a background of both previous AMI and lung disease. There was no definite clinical evidence offurther myocardial infarction (e.g. new electrocardiographic changes). However, it was felt that myocardial damage could not definitely be excluded.
DISCUSSION
Twenty-five of 26 patients admitted to coronary care unit with myocardial infarction had positive cTnI results. While in 22 of 24 patients with an AMI, the cTnI became positive at the same time as CKMB, in two patients it was later than CKMB. In routine diagnostic use cTnI became positive later than CKMB in four patients. Both these findings are expected from the work of Bodor et al? They found that although cTnI became positive for AMI somewhat later than CKMB there was overlap: mean (range) times for cTnI and CKMB becoming positive in AMI were 6·8 (2'7-19) and (1'9-19) h, respectively.
In patients admitted to CCU with chest pain, where AMI was subsequently ruled out, 84% had cTnI less than 0·5 Ilg/L. There were six patients out of 57 with cTnI between 1·0 and 1·5IlgjL. It is possible these patients have a worse long-term prognosis, as has been reported for cTnl concentrations in patients with acute coronary syndromes." cTnl provides useful prognostic information and has been reported to allow the early identification of patients at an increased risk of death."
Cardiac troponin I remained elevated for up to 183 h after the onset of chest pain in AMI. cTnI is found in cytosol as well as myofibrils.?
The initial increase in cTnI in AMI is probably due primarily to its release from the cytosol and the prolonged elevation is due to continued degradation and release of cTnl from myofibrils. The time between symptom onset and cTnl peak is correlated with the duration of elevation of cTnI. The shorter time to peak CK and CKMB values has been shown to occur in patients who reperfuse the coronary arteries after thrombolysis." Our findings for cTnI in limited number of patients are in keeping with those reported for CK and CKMB.
The much longer duration of elevation of cTnl after AMI as compared to CKMB elevation is reflected in the routine diagnostic use of cTnI. There were 8 samples where cTnl remained positive after CKMB became negative.
Cardiac troponin I is more specific than CKMB in patients with skeletal muscle damage. In five of six patients with extensive skeletal muscle damage cTnl was normal ( Table 2) . These findings are similar to those of Lofberg et al. 9 In the sixth patient cTnl was mildly elevated at 3·7IlgjL, in keeping with the clinical impression of some myocardial damage.
In all the athletes who ran a 21 km road race cTnl was normal. Cummins et al. reported that cTnl was increased in one of their eleven athletes I and 128 h after a marathon race.!? It was not increased in any of the athletes at 24 h. Their cTnl assay showed cross-reactivity with human skeletal muscle troponin I of less than 2%. In our study while CKMB concentrations were increased in 25% of samples 24 h after the race, the CKMB relative index was normal in all of them. Some studies have reported increased CKMB concentrations as well as CKMB relative index 3 .4. 1o while another has reported, like us, increase in CKMB concentration but not in CKMB relative index.'! In routine diagnostic use, nine patients had a positive cTnl and negative CKMB ( Table 3) . Five patients had a clear clinical diagnosis of AMI and further two had probable AMI. In two Troponin I and cardiac injury SIS patients there was no clinical evidence of AMI. Both had evidence of severe sepsis and cTnI was marginally elevated at 2·0 and 1·8 JigjL. Patients with sepsis may have elevated cTnl even if there is no other evidence of myocardial damage.'? These patients have a worse morbidity and mortality outcome.F
In seven patients where cTnI was negative and CKMB was positive, five did not have clinical evidence of myocardial infarction (Table 4 ). In the patient with AMI only one sample was available before the patient died. It is likely that the CKMB and cTnl were both increasing and had a second sample been taken a few hours later cTnl would have been positive. The possibility of myocardial infarction could not be ruled out in only one of the seven patients. In the group of 16 patients where there was a discrepancy between the CKMB and cTnl values (Tables 3 and 4 ), the efficiency of cTnl was 75% and CKMB was 25% in correctly identifying patients with an AMI.
CONCLUSION
Cardiac troponin I is just as sensitive as CKMB in patients admitted to coronary care unit shown to have had AMI, even though in a small proportion of patients its rise is a little later than CKMB. However, it is superior to CKMB in other respects. Cardiac troponin I is specific in patients with skeletal muscle damage and is very useful in these patients to confirm or exclude concurrent myocardial damage. cTnl remains elevated for a much longer period of time than CKMB. Finally, in routine diagnostic use there are fewer false positives and false negatives for cTnl than CKMB.
